1	Elevated plasma Complement Factor H Regulating Protein 5 is associated with venous							
2	thromboembolism and COVID-19 severity							
3								
4	One sentence summary: Elevated CFHR5 plasma concentration is associated with diagnosis							
5	and risk of venous thromboembolism, and with short-term prognosis in hospitalised COVID-19							
6	patients.							
7								
8	Laura Sanchez-Rivera ¹ †, Maria Jesus Iglesias ^{1,2,3} †, Manal Ibrahim-Kosta ⁴ , Julia Barbara Kral-							
9	Pointner ⁵ , Sebastian Havervall ⁶ , Louisa Goumidi ⁴ , Maria Farm ^{5,7} , Gaëlle Munsch ⁸ , Marine							
10	Germain ^{8,9} , Philip Smith ^{10,11} , Mun-Gwan Hong ¹ , Pierre Suchon ⁴ , Clément Naudin ^{1,3} , Anne							
11	Boland ^{12,13} , David M Smadja ^{14,15} , Margareta Holmström ¹⁶ , Maria Magnusson ^{5,16,17} , Angela							
12	Silveira ¹⁰ , Mathias Uhlén ¹ , Thomas Renné ^{18,19,20} , Angel Martinez-Perez ²¹ , Joseph Emmerich ²² ,							
13	Jean-Francois Deleuze ^{23,24,25} , Jovan Antovic ^{5,7} , Alice Assinger ²⁶ , Jose Manuel Soria							
14	Fernandez ²¹ , Charlotte Thålin ⁶ , Jochen M Schwenk ¹ , Juan Carlos Souto Andres ²⁷ , Pierre-							
15	Emmanuel Morange ^{4,*} , Lynn Marie Butler ^{1,3,5,7*} , David-Alexandre Trégouët ^{8,9,*} , Jacob							
16	Odeberg ^{1,2,3,10,16,*} .							
17	† Equal contribution							
18	*Equal contribution							
19								
20	Author affiliations:							
21	1. Science for Life Laboratory, Department of Protein Science, CBH, KTH Royal Institute of							
22	Technology, SE-171 21 Stockholm, Sweden							
23	2. Division of Internal Medicine, University Hospital of North Norway (UNN),							
24	PB100, 9038 Tromsø, Norway							
25	3. Translational Vascular Research, Department of Clinical Medicine, UiT The Arctic							
26	University of Norway, Tromsø, Norway.							

27	4.	Aix-Marseille Univ, INSERM, INRAE, C2VN, Laboratory of Haematology, CRB
28		Assistance Publique - Hôpitaux de Marseille, HemoVasc (CRB AP-HM HemoVasc),
29		Marseille, France.
30	5.	Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm,
31		Sweden.
32	6.	Division of Internal Medicine, Department of Clinical Sciences, Danderyd Hospital,
33		Karolinska Institutet, Stockholm, Sweden.
34	7.	Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
35	8.	University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR
36		1219, team ELEANOR, Bordeaux, France.
37	9.	Laboratory of Excellence GENMED (Medical Genomics), Bordeaux, France
38	10.	Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital,
39		Stockholm. Sweden.
40	11.	Theme of Emergency and Reparative Medicine, Karolinska University Hospital,
41		Stockholm, Sweden.
42	12.	CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay,
43		91057, Evry, France
44	13.	Laboratory of Excellence GENMED (Medical Genomics), Evry, France.
45	14.	Hematology Department and Biosurgical Research Lab (Carpentier Foundation),
46		European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, 20 rue
47		Leblanc, Paris, 75015, France
48	15.	Innovative Therapies in Haemostasis, INSERM, Université de Paris, 4 avenue de
49		l'Observatoire, Paris, 75270, France
50	16.	Coagulation Unit, Department of Haematology, Karolinska University Hospital, SE-171
51		76 Stockholm, Sweden

52 17. Department of Clinical Science, Intervention and Technology, Karolinska Institutet (KI),

- 53 171 77, Stockholm, Sweden
- 54 18. Institute for Clinical Chemistry and Laboratory Medicine, University Medical Centre
- 55 Hamburg-Eppendorf, D-20246 Hamburg, Germany
- 56 19. Center for Thrombosis and Hemostasis (CTH), Johannes Gutenberg University Medical
- 57 Center, D-55131 Mainz, Germany
- 58 20. Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences,
- 59 Royal College of Surgeons in Ireland, Dublin 2, D02 YN77, Ireland
- 60 21. Genomics of Complex Diseases Group. Research Institute Hospital de la Santa Creu i
- 61 Sant Pau. IIB Sant Pau, Barcelona, Spain
- 62 22. Department of vascular medicine, Paris Saint-Joseph Hospital Group, INSERM 1153-
- 63 CRESS, University of Paris Cité, 185 rue Raymond Losserand, Paris, 75674, France
- 64 23. Laboratory of Excellence GENMED (Medical Genomics), Evry, France.
- 65 24. CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay,
- 66 91057, Evry, France.
- 67 25. Centre D' Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France
- 68 26. Center for Physiology and Pharmacology, Institute of Vascular Biology and Thrombosis
 69 Research, Medical University of Vienna
- 27. Unitat d'Hemostàsia i Trombosi. Hospital de la Santa Creu i Sant Pau and IIB-Sant Pau,
 Barcelona, Spain.
- 72

73 Address correspondence to:

- 74 Jacob Odeberg
- 75 Science for Life Laboratory, Department of Protein Science, CBH, KTH Royal Institute of
- 76 Technology, SE-171 21 Stockholm, Sweden
- 77 Jacob.odeberg@scilifelab.se

- 78 **or**
- 79 David-Alexandre Trégouët
- 80 University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, team
- 81 ELEANOR, Bordeaux, France.david-alexandre.tregouet@u-bordeaux.fr

83 ABSTRACT

Venous thromboembolism (VTE), comprising both deep vein thrombosis (DVT) and pulmonary 84 85 embolism (PE) is a common, multi-causal disease with potentially serious short- and long-term 86 complications. In clinical practice, there is a need for improved plasma biomarker-based tools for 87 VTE diagnosis and risk prediction. We used multiplex proteomics profiling to screen plasma from 88 patients with suspected acute VTE, and a case-control study of patients followed up after ending 89 anticoagulant treatment for a first VTE. With replication in 5 independent studies, together totalling 90 1137 patients and 1272 controls, we identify Complement Factor H Related Protein (CFHR5), a 91 regulator of the alternative pathway of complement activation, as a novel VTE associated plasma 92 biomarker. Using GWAS analysis of 2967 individuals we identified a genome-wide significant 93 pQTL signal on chr1g31.3 associated with CFHR5 levels. We showed that higher CFHR5 levels 94 are associated with increased thrombin generation in patient plasma and that recombinant 95 CFHR5 enhances platelet activation *in vitro*. Thrombotic complications are a frequent feature of 96 COVID-19; in hospitalised patients we found CFHR5 levels at baseline were associated with 97 short-time prognosis of disease severity, defined as maximum level of respiratory support needed 98 during hospital stay. Our results indicate a clinically important role for regulation of the alternative 99 pathway of complement activation in the pathogenesis of VTE and pulmonary complications in 100 acute COVID-19. Thus, CFHR5 is a potential diagnostic and/or risk predictive plasma biomarker 101 reflecting underlying pathology in VTE and acute COVID-19.

103 INTRODUCTION

104 Venous thromboembolism (VTE), comprising both pulmonary embolism (PE) and deep vein 105 thrombosis (DVT) is a common, multi-causal disease with serious short and long-term 106 complications. VTE has a high mortality rate in the first year, especially within the first 30 days 107 (~30% for PE) and a high risk of recurrence, with a cumulative incidence rate of 25% within 10 108 vears [1-4]. VTE diagnosis is challenging, as the predisposing common risk factors and clinical 109 presentation can be consistent with multiple other conditions, particularly in the case of PE. 110 Current VTE diagnostic work-up includes assessment of clinical probability, using clinical decision 111 rules, e.g., the Well's score, in combination with elevated plasma D-dimer levels [5, 6]. However, 112 D-dimer, a clot breakdown product, can be elevated in several other non-VTE conditions (e.g., 113 inflammation, surgery, cancer). Thus, its usefulness is limited to ruling out VTE in low probability 114 cases. In medium and high probability cases, diagnostic imaging, i.e., compression ultrasound 115 (CUS) on suspicion of DVT, or computed tomography pulmonary angiogram (CTPA) on suspicion 116 of PE, is necessary to exclude or confirm diagnosis. These tests may not be readily available in 117 the acute setting, resulting in delayed or incorrect diagnosis. Today, less than 20% of CTPAs and 118 CUS confirm suspected PE [7-9] or DVT [10], respectively. Specific biomarker-based tools in the 119 diagnostic workup could reduce unnecessary imaging, save resources and, in the case of CTPA, 120 reduce exposure to radiation and contrast agent. Several studies have proposed VTE biomarker 121 candidates (e.g., p-selectin, microvesicles) [11], but none have reached clinical implementation. 122 There is also a need for improved tools and plasma biomarkers for risk prediction in VTE. Risk 123 scores based on clinical risk factors and D-dimer levels have been developed for recurrence 124 prediction [12-18], but none are routinely integrated into clinical practice. In addition to the genetic 125 variants currently used in clinical assessment of hereditary thrombophilia (e.g., Factor V Leiden, 126 prothrombin mutation) there are other more recently discovered common gene variants that 127 contribute to VTE risk [19-21]. However, even when these are also incorporated into risk scores, 128 they still lack sufficient precision for VTE prediction on an individual basis [22, 23]. This likely

reflects the interplay between transient and sustained risk factors in disease development, including acquired risk factors, genetics, and environmental exposures [24, 25].

131 VTE is a disease of the intravascular compartment and thus analysis of the blood proteome has 132 the potential to capture the resulting effects of combined genetic, epi-genetic, and environmental 133 contributors to risk variation. Large scale plasma proteomics screening allows for discovery of 134 novel protein biomarkers with potential clinical utility for diagnosis and/or prediction. Such studies 135 could also reveal biological pathways involved in VTE pathogenesis, for further functional studies 136 to identify targets for tailored treatment. So far, a handful of plasma proteomics studies of VTE 137 have been reported, presenting novel candidates associated with increased risk of VTE [26-30], 138 including our own; the first affinity proteomics case-control study of patients followed up post 139 treatment after a first VTE, reporting PDGFB as a novel VTE associated biomarker [27]. High 140 throughput affinity proteomics studies have increased the capacity for discovery screening and 141 identification of novel associations, as now it is possible to screen for hundreds or thousands of 142 proteins in small plasma volumes [31]. Orthogonal verification is essential to confirm results 143 generated using these technologies but is frequently absent from such studies.

144 Here, we aimed to identify novel biomarkers associated with acute VTE with a potential link to 145 underlying VTE pathogenesis. We identified complement factor H-related protein 5 (CFHR5), a 146 regulator of the alternative pathway of complement activation, as a novel VTE associated plasma 147 biomarker. Furthermore, we found that CFHR5 plasma levels are associated with short term 148 prognosis in acute COVID-19, a disease where thrombosis formation is central to pathology. Our 149 study suggests that CFHR5 could be involved in the underlying pathogenesis of VTE and acute 150 COVID-19, and that it is a potential clinical biomarker for thrombotic disease diagnosis and/or risk 151 prediction.

152

154 **RESULTS**

155 Affinity plasma proteomics identifies candidate proteins associated with acute VTE

156 To identify plasma biomarkers for VTE we analysed samples collected as part of our Venous 157 thromboEmbolism BIOmarker Study (VEBIOS) [27]. VEBIOS comprises two study arms; a 158 prospective cohort of patients sampled at the Emergency Room (ER), Karolinska University 159 Hospital, Sweden (VEBIOS ER) and a case/control study with patients sampled at an outpatient 160 coagulation clinic after discontinuation of anticoagulant treatment after a first VTE (VEBIOS 161 Coagulation). The discovery cohort, VEBIOS ER (Figure 1A), consisted of patients (n= 147) 162 admitted to the ER with the suspicion of DVT in the lower limbs and/or PE. Following admission, 163 two whole blood samples were collected from participants, into citrate and EDTA anticoagulant. 164 Patient samples were classified as controls (n=96), when a VTE diagnosis was excluded by 165 diagnostic imaging, and/or Well's clinical criteria with a normal D-dimer test, or cases (n=51) when 166 VTE was confirmed by diagnostic imaging and anticoagulant treatment was initiated. A nested 167 case/control sample set of 48 cases and 48 matched controls were selected for plasma protein 168 analysis (Table 1). Target candidates for measurement were selected as previously described 169 [27], based on: (i) indications from the literature, in house data or public repositories of a probable 170 or plausible link to arterial or venous thrombosis (e.g., prior evidence of association with 171 thrombosis or intermediate traits, or known involvement in biological pathways of relevance), 172 including 124 that we predicted to have endothelial enriched expression [32], and (iii) the 173 availability of target specific antibodies in the Human Protein Atlas (HPA). A total of 758 HPA 174 antibodies, targeting 408 candidate proteins, were selected for incorporation into a single-binder 175 suspension bead array (Figure S1 A and Table S1, Tab 1), which was used to analyse plasma 176 generated from the blood samples collected into citrate anticoagulant. The signal generated by 177 antibody HPA059937, raised against the protein target sulfatase 1 (SULF1), was most strongly 178 associated with VTE (p<8.34E-06) (Figure 1B, green point), with higher relative plasma levels in 179 cases vs. controls (Figure 1D.i). Signals generated by a further seven antibodies were also

180 associated with VTE (p<0.01) (Table S1, Tab 1). Protein signatures in plasma can be differently 181 affected by the sample matrix; anticoagulants can inhibit specific proteases, influence soluble 182 protein interactions, and modify analyte stability. Thus, the anticoagulant type used has potential 183 consequences for biomarker identification [33]. We therefore replicated the VEBIOS ER discovery 184 screen in EDTA samples drawn in parallel from the same patients (Figure 1C). Of the eight 185 antibodies that produced signals associated (p<0.01) with VTE in the citrate samples (Table S1, 186 Tab 1), four were replicated in the EDTA samples (Figure 1B and C): HPA059937 (predicted 187 target SULF1, green point), HPA044659 (predicted target Leukocyte surface antigen CD47 188 [CD47], blue point), HPA003042 (predicted target Adenosine receptor A2a [ADORA2A], orange 189 point) and HPA002655 (predicted target P-Selectin [SELP], red point) (Table S1, Tab 1). In both 190 anticoagulants, all four target candidates were elevated in cases vs. controls (Figure 1D and E, i-191 iv). In all subsequent experiments, citrated blood was used in the analysis, on the basis that it is 192 the more commonly used sample anticoagulant in the clinical setting for coagulation analyses.

193 Previously, in the VEBIOS Coagulation study (n=177) [27], we identified 29 protein candidates in 194 plasma that were associated with prior VTE. This study was composed of patients sampled 1-6 195 months after discontinuation of anticoagulation treatment (duration 6-12 months) following a first 196 time VTE, or matched controls. Of the four antibodies that generated signals associated with 197 acute VTE in citrate and EDTA plasma in VEBIOS ER (Figure 1B and C, marked with coloured 198 circles), only HPA059937 (predicted target SULF1), produced a signal associated with prior VTE 199 in the VEBIOS Coagulation study [27]. As our aim was to identify biomarkers associated with 200 acute VTE that were potentially linked to the underlying disease pathogenesis, we prioritised this 201 candidate on the basis that higher plasma concentrations observed in individuals with a 202 documented increased risk of VTE (e.g., previous VTE) in VEBIOS Coagulation study indicated 203 that it could also represent a constitutive and/or persistent risk factor.

204 Complement Factor H Related protein 5 (CFRH5) is associated with VTE

205 The antibodies used in the single-binder suspension bead arrays passed quality control for 206 antigen binding specificity (see www.proteinatlas.org/), but selective binding to the target protein 207 in context of the complex matrix of plasma requires verification, as antibody specificity and 208 reliability can be a problematic issue [34-36] (Figure S1 C-F). To verify which protein(s) were 209 captured by HPA059937 (predicted target SULF1) we performed immunocapture-mass 210 spectrometry (IC-MS). Two proteins were bound to HPA059937 with a z-score>3 in triplicate 211 experiments; the predicted target, SULF1 (z-score = 4.02, with 1 Peptide Spectrum Match [PSM]), 212 and Complement Factor H Related protein 5 (CFHR5) (z-score=5.09, with ≥21 PSM) (Figure 1F 213 and Table S1, Tab 2). These data indicate that CFHR5 was the predominant protein captured by 214 HPA059937 in plasma, whilst not ruling out concurrent binding of SULF1. High levels of CFHR5 215 have been detected in plasma by mass spectrometry (MS) [37], but SULF1 (a protein predicted 216 to be localised on the cell surface) is below the MS detection threshold [38]. To further verify 217 CFHR5 binding specificity of HPA059937, we developed three dual binder assays (Figure S1B 218 and Figure 1G), all with a commercial monoclonal antibody against CFHR5 as a detection 219 antibody, combined with either: original antibody HPA059937 (Figure 1G.i), or one of two 220 independent antibodies raised in house against CFHR5; HPA073894 (Figure 1G.ii) or 221 HPA072446 (Figure 1G.iii), as bead coupled capture antibodies. When used to re-analyse the 222 VEBIOS ER samples; all three assays consistently detected a higher level of target protein in 223 cases vs. controls (Figure 1G iv-vi, p=0.0001, 0.0021, 0.0006, respectively). Furthermore, MFI 224 values from all three strongly correlated with those generated by HPA059937 in the VEBIOS ER 225 discovery screen (Figure 1G.vii-ix) (Spearman correlation 0.86, 0.78 and 0.84, respectively [all 226 p<0.00001]). We made five dual binder assays that targeted SULF1, but none gave a quantitative 227 signal in a plasma dilution series, or buffer containing a dilution series of recombinant SULF1 228 protein. These data are consistent with CFHR5, as opposed to SULF1, being the target protein 229 associated with VTE in the VEBIOS ER discovery screen.

230 CFHR5 is associated with VTE independent of D-dimer or CRP

231 The CFHR5 dual binder assay using capture antibody HPA072446 (Figure 1G.iii), together with 232 recombinant CFHR5 protein standard, was used for absolute quantification of CFHR5 in VEBIOS 233 ER and an extended sample set of the VEBIOS Coagulation study (n=284) (Table S2, Tab 1 for 234 cohort descriptive data). In the VEBIOS ER and Coagulation study, mean CFHR5 concentrations 235 in control plasma samples were 2842 ± 756 and 2467 ± 523ng/ml, respectively; levels in the range 236 previously estimated by mass spectrometry (~1900ng/ml) [37]. In the VEBIOS ER discovery 237 study, the mean absolute CFHR5 concentration was confirmed as higher in patients with 238 confirmed VTE, compared to patients where VTE was ruled out ($3428 \text{ ng/ml} \pm 774$ [cases] vs. 239 2842 ng/ml ± 756 [controls], p=1.05E-03 [age and sex adjusted]); the odds ratio (OR) for diagnosis 240 of acute VTE associated with one standard deviation (SD) increase of CFHR5 concentration was 241 2.54 [confidence interval (CI) 1.52-4.66], p=1.05E-03 (Figure 1H.i). Consistent with the relative 242 quantification results in our previous study [27], absolute CFHR5 concentration was associated 243 with prior diagnosis of VTE in the extended VEBIOS Coagulation cohort, compared to controls 244 (mean concentration 2681 ng/ml \pm 554 [cases] vs. 2467 ng/ml \pm 523 [controls], p= 8.42E-04 [age 245 and sex adjusted]); the OR for first time VTE was 1.55 [Cl 1.20-2.01], p=8.85E-04) (Figure 1J.i). 246 We next investigated if CFHR5 levels were associated with VTE associated risk factors, such as age, body mass index [BMI]) and routine clinical laboratory tests for blood markers associated 247 248 with thrombosis risk (e.g., D-dimer, c-reactive protein [CRP], thrombocyte count). In VEBIOS ER, 249 CRP levels correlated with plasma CFHR5 concentration, in cases (ρ =0.57, p<0.001) and controls 250 $(\rho=0.52, p<0.001)$ (Figure 1H.ii), but there was no strong correlation between CFHR5 and the 251 other parameters measured, in cases or controls, including D-dimer (Figure 1H.iii and Table S1, 252 Tab 3, Table A). In the VEBIOS Coagulation study, CFHR5 levels in cases correlated with both 253 CRP (ρ =0.49, p<0.001) and D-dimer (ρ =0.42, p<0.0001) (Figure 1J.ii and iii, right panel), but in 254 controls these correlations were weak (CRP ρ =0.24, p=0.005) or absent, respectively (Figure 255 1J.ii, and iii, left panel and Table S1, Tab 3, Table B). The association between CFHR5 and VTE

remained significant in both *VEBIOS ER* (p=0.0029) and *VEBIOS Coagulation* (p=0.0015) when
adjusted for CRP. Therefore, we did not adjust for CRP in further analyses.

258 CFHR5 is specifically expressed in liver hepatocytes with other complement related genes 259 To further understand the expression characteristics of CFHR5, and to identify possible co-260 expressed or co-regulated proteins we used a whole transcriptome analysis approach. In a 261 consensus dataset, consisting of normalized mRNA transcript (nTPM) levels across 55 different 262 human tissue types, generated from Human protein Atlas (HPA) (www.proteinatlas.org) [39] and 263 Genotype-Tissue Expression Project (GTEx) (www.gtexportal.org) [40] datasets, CFHR5 was 264 highly and specifically expressed in the liver (Figure 2A). Single cell analysis of liver tissue [41], 265 showed that CFHR5 was specifically expressed in the hepatocyte cellular compartment (Figure 266 2B). To identify transcripts potentially co-expressed or co-regulated with CFHR5 in the liver, we 267 analysed bulk RNAseq data (n=226) retrieved from GTEx portal V8. We generated Pearson 268 correlation coefficients between CFHR5 and all other expressed protein coding transcripts 269 (~19,525) (Table S1, Tab 4, Table A) and used gene ontology (GO) and reactome analysis [42, 270 43] to identify over-represented classes and pathways in the top 50 most highly correlated genes 271 (Table S1, Tab 4, Table B and C). Results were consistent with known CFHR5 function; 272 significant GO terms included 'complement activation' (False Discovery Rate, FDR =2.4E-16) 273 and 'humoral immune response' (FDR =1.2E-12) and reactome pathways included 'regulation of 274 complement cascade' (FDR=3.8E-24). We performed an unbiased weighted network correlation 275 analysis (WGCNA) [44] on the same dataset, where correlation coefficients between all 276 transcripts, excluding those classified as non-coding, were calculated and subsequently clustered 277 into related groups, based on expression similarity (Table S1, Tab 4, Table A [column F]). 278 Transcripts that fulfilled the criteria of: (i) Pearson correlation with CFHR5 > 0.65 and (ii) annotation 279 to the CFHR5-containing gene cluster in WGNCA (group 68), were identified as those most likely 280 to be co-expressed or co-regulated. Of these, 13/18 [72%] were other members of the 281 complement cascade and 15/18 [83%] were also specifically expressed in liver [39] (Table S1,

Tab_4, Table A, column F) (Table S1, Tab_4, Table A, column B, bold text). When these proteins were interrogated using the protein-protein interaction database STRING, v11 [45], 13/18 had high confidence functional and physical associations (Figure 2C) (Table S1, Tab_5, Table A). CFHR5 was most strongly linked to complement 3 (C3), the central hub of the largest of the three linked cluster groups identified (Figure 2C, clusters represented by green, red and cyan) (Table S1, Tab 5, Table B).

288 CFHR5 is associated with VTE independent of C3

289 Plasma levels of C3 have previously been reported as associated with incident VTE [46]. To 290 determine if the association between CFHR5 and VTE we observed is dependent or independent 291 of the relationship with C3, we developed an in-house dual binder quantitative assay to measure 292 C3 in the VEBIOS ER and VEBIOS Coagulation cohorts. In VEBIOS ER, plasma C3 was not 293 elevated in cases, compared to controls (Figure 2D.i), CFHR5 and C3 did not significantly 294 correlate in either group (Figure 2D.ii) and C3 was not associated with VTE (OR 1.04 [CI 0.68-295 158], p=0.86). Conversely, in VEBIOS Coagulation C3 levels were higher in plasma from cases, 296 compared to controls (Figure 1E.i), and CFHR5 and C3 correlated with each other in both 297 ([controls $\rho = 0.46$ p=<0.0001], [cases $\rho = 0.47$ p=<0.0001]). After adjusting for age and sex, one 298 SD increase in C3 level was significantly associated with VTE (OR 1.53 [CI 1.18-2.01], p=1.93E-299 03). When adjusting for C3 together with age and sex, one SD increase in CFHR5 level was still 300 associated with VTE in both VEBIOS ER (OR 2.65 [CI 1.53-5.01], p=0.00126) and VEBIOS 301 Coagulation (OR 1.37 [CI 1.03-1.83], p=0.032). In contrast, when adjusting for CFHR5 together 302 with age and sex, C3 was no longer significantly associated with VTE in VEBIOS Coagulation 303 (OR 1.31 [CI 0.99-1.78], p=0.0645). Thus, CFHR5 is associated with both a diagnosis of acute 304 VTE and prior VTE, independent of C3.

305 The CFHR5 association with VTE replicates in additional cohorts

306 The identification of biomarkers associated with VTE diagnosis, or risk profiling, requires 307 replication in independent cohorts, from different settings with different demographic profiles, to

308 determine feasibility for potential translation to clinical practice. We sourced three independent 309 replication cohorts to test the association of CFHR5 with VTE; the Swedish Karolinska Age 310 Adjusted D-Dimer study (DFW-VTE) VTE study (n=200) consisting of patients sampled at 311 presentation with suspected VTE at Huddinge hospital. Stockholm that was either subsequently 312 confirmed (cases; n=54) or ruled out (controls; n=146) [47] (Figure 3B), the French FARIVE 313 case/control study (n=1158) consisting of patients sampled during the week following a diagnosis 314 of acute VTE (n=582), with hospital-based controls (n=576) [48] (Figure 3C) and the Spanish 315 Riesgo de Enfermedad TROmboembólica VEnosa (RETROVE) study (n=668) of patients 316 sampled post anticoagulant treatment (n=308), with population based controls (n=360) [49] 317 (Figure 3E) (for all cohort details see Table S2, Tabs 2-4). The relative risk of VTE associated 318 with CFHR5 per 1 SD increase in CFHR5 concentration was significant in all 3 replication cohorts: 319 DFW-VTE (OR 1.80 [CI 1.29-2.58], p=0.0008) (Figure 3B), FARIVE (OR 1.24 [CI 1.10-1.40], 320 p=0.0004) (Figure C), RETROVE (OR 1.29 [CI 1.09-1.53], p=0.002) (Figure 3E) (Table 2). In all 321 cohorts, including VEBIOS ER and VEBIOS Coagulation, association results were comparable in 322 sub-set analysis by thrombosis type (Table S1, Tab 6, Table A) or sex (Table S1, Tab 6, Table 323 B). When samples from cases and controls were stratified according to CFHR5 concentration, 324 the association with VTE risk was most pronounced in the third tertile, in all 5 cohorts analysed 325 (Table 2).

326 **CFHR5 and risk of recurrent VTE**

The MARseille THrombosis Association Study (MARTHA) is a hospital-b ased cohort of over 1,500 unrelated individuals recruited at the Thrombophilia center of La Timone hospital (Marseille, France). All patients had a history of a first VTE documented by venography, Doppler ultrasound, angiography and/or ventilation/perfusion lung scan [50]. We measured plasma CFHR5 concentrations in samples from VTE patients where follow up data was available (n=669) (for cohort details see Table S2, Tab_5). Using a Cox survival model with left truncature on the VTE cases we tested for association between CFHR5 and recurrence. In total, there were 124

334 recurrent events (52 among 231 males, 72 among 438 females). After adjusting for sex, familial 335 history of VTE, provoked or unprovoked status of the first VTE, age at first VTE, and BMI, the 336 Hazard Ratio (HR) associated of 1 SD increase in CFHR5 levels was HR = 1.13 [0.96-1.32], p = 337 0.134. The association was consistent between females (HR = 1.11) and males (HR = 1.14) and 338 between patients with DVT (HR = 1.18) or PE as first event (HR=1.13). This association was 339 driven by the subgroup of patients with unprovoked first VTE (HR = 1.32 [0.99 - 1.77], p=0.056). 340 as no association was observed when the first event was provoked (HR = 1.01 [0.83 - 1.23], 341 p=0.900). However, the testhomogeneity between these two HRs did not reach 0.05 significance 342 (p = 0.23).

343 Genome Wide Association Study on CFHR5 plasma levels

344 To explore if CFHR5 concentration in plasma was influenced by genetic variants, we performed 345 a meta-analysis of GWAS data CFHR5 concentrations in individuals from the FARIVE (n=1,033), 346 RETROVE (n=668) and MARTHA (n=1,266) studies. The results from the association results are 347 summarised in Figure 4A. Of N= 7,135,343 SNPs tested in a total sample of 2967 individuals, one 348 genome-wide significant (p < 5E-08) signal was observed on chr1g31.3. The lead SNP at this 349 locus was rs10737681, mapping to CFHR1/CFHR4, and the G allele was associated with β = 350 +81.33 \pm 8.67 (p = 6.49E-21) increase in CFHR5 levels. After conditioning on the rs10737681, a 351 borderline significant association (p = 9.83E-08) was observed at the rs10494747 where the A-352 allele tended to associate with an increase of β = +47.60 ± 8.92 in CFHR5 levels. Rs10494747 is 353 distant of ~343 kb from CFHR2 rs10737681, maps to ZBTB41 (Figure 4B) and was in moderate 354 linkage disequilibrium ($r^2 \sim 0.10$, D' = - 0.63) with the lead rs10494747 variant. Together, these two 355 variants only explained 2.2% of the inter-individual variability in CFHR5 plasma levels. Neither 356 SNP was associated with VTE risk in the FARIVE and RETROVE case-control samples (Table 357 S1, Tab 7).

358 CFHR5 enhances platelet activation and degranulation in plasma

359 C3a, generated by cleavage of C3, can increase platelet activation [51-53]. As CFHR5 has a 360 regulatory role upstream of C3/C3a activation, we investigated the effect of recombinant CFHR5 361 on platelet activation in vitro. Platelet rich plasma was pre-incubated with 6µg/ml recombinant 362 CFHR5, a concentration corresponding to the upper range of that detected in the plasma of the 363 VTE case group in VEBIOS ER, and in agreement with what has been reported in previous 364 literature [54]. Platelet activation was measured by surface expression of P-selectin, activated GP 365 IIb/IIIa or CD63 (Figure 5A, B and C, respectively) in response to adenosine diphosphate (ADP), 366 convulxin or TRAP6 (Figure 5 i, ii and iii, respectively). Under baseline conditions (in the absence 367 of stimulation) activation was not modified by pre-incubation with CFHR5 (Figure 5A.i-iii). 368 Following stimulation with ADP, a higher percentage of platelets pre-incubated with CFHR5 369 expressed P-selectin (Figure 5A.i) (p=0.0056), activated GP IIb/IIIa (Figure 5B.i) (p=0.031) and 370 CD63 (Figure 5C.i) (p=0.009), compared to the control. Pre-incubation with CHFR5 also 371 potentiated platelet activation in response to convulxin or TRAP6 stimulation (Figure 5A-C.ii and 372 iii), although the effect appeared to be more strongly linked to stimulus concentration, than that 373 observed for ADP. Washed platelet response to ADP, convulxin or TRAP6 was not modified by 374 preincubation with CFHR5 (Figure S2) (ANOVA all p>0.05), indicating that additional components 375 in plasma are required for the observed effects, and that they are not a direct effect of CFHR5 on 376 platelets. These data are consistent with the concept that CFHR5 is involved in the underlying 377 pathology of VTE.

378 CFHR5 is associated with thrombin generation potential in patients with previous VTE

As thrombin generation has been associated with increased risk of VTE [55], we tested the association between CFHR5 plasma concentration and thrombin generation as measured by thrombinoscope in *MARTHA* (n=774 VTE cases, see Table S2, Tab_5 for details) with replication in *RETROVE* (308 cases/360 controls, see Table S2_Tab_4 for details). In both *MARTHA* and *RETROVE* cases, we find significant association between CFHR5 and lag time (rho=0.181, p= p<0.0001 and rho=0.176, p<0.0001, respectively), Endogenous Thrombin Potential (ETP)

(rho=0.105, p= 0.0036, and rho=0.130, p<0.0001, respectively), peak (rho=0.117, p= 0.0012, and
rho=0.132, p<0.0001), and ttPeak (rho=0.116, p=0.0012, and rho=0.086, p=0.0274 (see Table
S1, Tab 8).

388 Plasma CFHR5 is associated with prognosis and respiratory status in COVID-19 patients

389 Accumulating evidence shows that vascular dysfunction, a prothrombotic state and complement 390 activation underlies severe COVID-19 pathophysiology, manifested as respiratory failure linked 391 to microvascular thrombosis in lung [56, 57]. Furthermore, VTE is a frequent complication in 392 hospitalized COVID-19 patients [58]. To determine if CFHR5 was associated with COVID-19 393 severity, we measured relative plasma levels in 339 samples collected at consecutive timepoints 394 from 112 hospitalised COVID-19 patients in the COVID-19 biomarker and Immunity 395 (COMMUNITY) study [59] (Figure 6A) (cohort details see Table S2, Tab 6), using a single binder 396 assay (antibody HPA073894). At each sampling timepoint, we categorised patients into one of 397 four 'Respiratory support Index' (RI) groups, as a proxy variable for COVID-19 severity: **RI 0**: no 398 respiratory support required, **RI 1**: \leq 5 Litres of oxygen on nasal cannula or mask, **RI 2**: > 5 Litres 399 of oxygen on nasal cannula or mask, RI 3: non-invasive ventilation/high-flow nasal cannula, or RI 400 4: intubation (Figure 6B). CFHR5 levels were positively associated with patient RI at the time of 401 sample collection (p=<0.0001, ANOVA) (Figure 6C.i). To determine if the measurement of plasma 402 CFHR5 at admission had potential value for prognosis, we performed a longitudinal analysis to 403 determine the association with maximum respiratory support index (max RI) registered at any 404 sampling time point during the hospital stay. CFHR5 at baseline was associated with the 405 maximum level of respiratory support required (Figure 6C.ii) (p=<0.0022, ANOVA). Therefore, 406 CFHR5 levels measured early upon admission carry short-term prognostic information of disease 407 development.

409 **DISCUSSION**

410 Here, we aimed to identify biomarkers associated with acute VTE that are linked to disease 411 pathogenesis. Using a nested case-control study, derived from a cohort of patients presenting to 412 the ER with suspected acute VTE, and from a case-control study with patients that had suffered 413 a previous first VTE, we identify CFHR5, a regulator of the alternative complement activation 414 pathway, as such a biomarker. The association of CFHR5 with current or previous VTE was 415 replicated in three additional cohorts or case-control studies, and we also found a trend for 416 association with risk for recurrence of unprovoked VTE. We identify a genome-wide significant 417 signal associated with CFHR5 levels located in the CFHR1-5 gene cluster loci. We further provide 418 evidence of a direct role of CFHR5 in the induction of a pro-thrombotic phenotype, through its 419 effect on platelet activation. Finally, we show that increased CFHR5 was associated with degree 420 of respiratory insufficiency and prognosis in acute COVID-19. Our findings indicate CFHR5 has 421 potential application as a clinical biomarker for VTE diagnosis and risk prediction, providing further 422 support to the idea that complement regulation is a key element of VTE pathogenesis.

423 Currently, D-dimer is the only plasma biomarker used in VTE diagnostic work-up, but its clinical 424 utility is limited to ruling out VTE in low-risk patients. Several studies have attempted to identify 425 novel biomarkers with potential clinically usefulness for the confirmation of VTE diagnosis, and 426 although a number have been identified [11], none have yet been implemented in clinical practice. 427 For many, like D-dimer, elevated levels are a consequence of thrombosis formation, e.g. 428 biomarkers of fibrinolysis, clot re-modelling or resolution (e.g. MMPs), inflammation secondary to 429 local vascular and tissue injury (e.g., CRP, IL-6, IL-10, fibrinogen), or of endothelial and/or platelet 430 activation (e.g. vWF, P-selectin) [11, 60, 61].

We find no correlation or association between D-dimer and CFHR5 in the acute VTE setting, supportive that increased concentration at diagnosis is not secondary to thrombus formation. In contrast, we found a strong correlation between D-dimer and CFHR5 levels in patients followed up after ending treatment for a first VTE, but not in controls. D-dimer has been associated with

increased risk of first and recurrent VTE [12-18, 62] and thus, our results are consistent with a
link between CFHR5 and subclinical coagulability in these patients at follow-up, possibly due to
persistent risk factors.

438 CFHR5 shares sequence and structural homology with Complement Factor H (CFH) [63], the 439 main negative regulator of alternative pathway (AP) activation in plasma [64]. Under normal 440 conditions, the AP is constitutively active through spontaneous hydrolysis of the thioester bond in 441 C3 and the formation of the initial fluid phase C3 convertase, C3(H₂O)Bb, which cleaves C3 into 442 C3a and C3b [64]. CFH promotes decay of the alternative and classical pathway convertases and 443 is a cofactor in the cleavage of C3b, hereby regulating excess activation of C3 [65]. CFH inhibits 444 C3 convertase by competing with Complement Factor B (CFB) for binding to C3, preventing 445 formation of C3a. CFHR5 antagonizes CFH function, through competitive binding to C3b and its 446 fragment C3d [66], thus deregulating AP activation. CFHR5 also promotes complement activation 447 by interfering with CFH binding to CRP, pentraxin 3 (PTX3), and extracellular matrix (ECM) [67]. 448 The complement and haemostatic systems interact at several points during initiation, propagation, 449 and regulation of complement activation and coagulation [68]. Studies have indicated a role of 450 complement in VTE pathogenesis [46, 52], but underlying mechanisms are not well understood. 451 Elevated plasma C3 in baseline samples has been shown to be associated with increased risk of 452 future VTE [46]. Consistent with these findings, C3 was associated with prior VTE in the VEBIOS 453 coagulation study, but not with acute VTE in the VEBIOS ER study. In both cases, and in the 454 previous study by Nordgaard et. al. [46], total C3 level, rather than the active form (C3a) is 455 measured; it is possible that in acute VTE, regulation of C3 convertase (by CFHR5) is important, 456 rather than absolute C3. It could be speculated that the association of C3 with VTE in individuals 457 sampled pre-VTE [46] or following treatment, reflects co-regulation of CFHR5 and C3 under basal 458 conditions, where C3 is a proxy for CFHR5, where CFHR5 represents the functional link to VTE 459 risk, rather than C3 levels per se. Consistent with this idea, in the VEBIOS coagulation study, the 460 association between CFHR5 and previous VTE remained significant when adjusted for C3.

461 The CFHR5 locus maps to chromosome 1g31.3 at one end a gene cluster that spans 462 approximately 350 kb and that includes (in order from CFHR5) the CFHR2, CFHR4, CFHR1, 463 CFHR3, and CFH loci (Figure 4B). The rs10737681 we identify with genome wide association 464 with CFHR5 levels maps between the CFHR4 and CFHR1 genes (Figure 4B). Of note, 465 the CFHR2 locus has just been identified as a novel susceptibility locus for VTE in the recently 466 published international effort on VTE genetics [21]. The lead SNP at this locus is rs143410348, 467 which is in moderate LD with the rs10737681 ($r^2 = 0.38$ in *FARIVE*) that here we found associated 468 with CFHR5 plasma levels. Unfortunately, rs143410348 was not imputed in MARTHA nor in 469 RETROVE, preventing us from investigating its association with CFHR5 plasma levels in our 470 meta-analysis. Nevertheless, in FARIVE where it was imputed, its association with CFHR5 levels 471 tended to be slightly less pronounced than that observed with rs10737681 (+76.4 \pm 27.0; p = 472 $4.8E-03 \text{ vs} + 101.5 \pm 29.1; \text{ p} = 5.06E-04)$. Altogether, these observations emphasize the need for 473 a deeper investigation of the genetic architecture of the CFHR1/CFHR4/CFHR2/CFHR5 474 locus with respect to VTE risk.

475 Our study indicates that CFHR5 has a possible role in the potentiation of platelet activation. Using 476 a flow restricted tissue-factor dependent mouse model of VTE, Subramaniam et. al. showed that 477 C3 and C5 affected platelet activation and tissue factor procoagulant activity by different 478 mechanisms, independent of formation of the terminal complement C5b-C9 complex [53]. In 479 ligated inferior vena cava, both C3 deficient and C5 deficient mice developed smaller thrombi, 480 with reduced fibrin deposition compared to the wild type. C3, but not C5, deficient mice had 481 reduced platelet activation ex vivo, reduced platelet deposition in vivo, and reduced thrombosis 482 incidence (<30 vs. 80% in wild type). These data indicate that in VTE C3 has an important role in 483 initial hemostasis, independent of downstream complement proteins [52]. C3a, acting through 484 platelet receptor C3aR, has an important role in the activation of the Gp3a/2b fibrinogen receptor 485 via intraplatelet signaling, and subsequent thrombosis formation [51]. Similar to the study of 486 Subraminam et. al. [53], Sauter et. al. showed C3 deficient mice had prolonged bleeding time,

487 that could be reversed by intravenous administration of C3a peptide [51]. The C3a-C3aR induced 488 intracellular signaling was mediated through the Rap1b activation, where co-stimulation of 489 platelets with C3a-ADP resulted in increased Rap1b activity on top of the platelet stimulation by 490 only ADP. In our study, we observe a similar co-stimulatory effect of CFHR5 on ADP- (and 491 convulxin- or TRAP6-) induced platelet activation. This effect was observed on platelets in 492 plasma, but not on those that were pre-washed, consistent with the effect of CFHR5 on platelet 493 activation being due to its interaction with other complement factors (i.e., C3) in plasma. On basis 494 of these recently published mechanistic findings, our in vitro results indicate that CFHR5 495 regulation of the alternative pathway of activation has an important role in C3a mediated platelet 496 activation in thrombosis, providing a potential functional link to its association with acute VTE.

497 Our findings indicate that CFHR5 mediated dysregulation of the AP could play an important role 498 in COVID-19 progression. Acute respiratory distress syndrome (ARDS) is the most common 499 serious complication of COVID-19 [69], where patients suffer from dysregulated haemostasis. 500 presenting with atypical ARDS [69, 70] with thrombosis formation in the lung microvasculature 501 [71]. Other studies have shown that severe disease is associated with complement activation [56]. 502 and the cross-talk between coagulation and complement contributes to elevated coagulopathy 503 and thromboembolic complications [72]. Furthermore, elevated complement activation has been 504 correlated with disease severity and development of ARDS in hospitalised COVID-19 patients 505 [72] and patients with severe COVID-19 have a higher incidence of VTE [73].

506 Our study has various strength and limitations; *VEBIOS ER*, the discovery cohort, that was 507 derived from a single centre, where blood sampling for plasma biobanking was performed in 508 parallel to that for routine tests after initial evaluation (before diagnostic imaging or anticoagulant 509 treatment), thus avoiding bias in inclusion or biobanking. Samples were handled according to 510 standard clinical chemistry lab routine, thus variations in needle-to-spin-to-freeze time were 511 equivalent between case and control samples. As biobanking was based on the routine sample 512 flow, this increases the feasibility that identified biomarker candidates are suitable for clinical

513 translation into a routine setting. Importantly, we demonstrate an association of CFHR5 with VTE 514 in several independent studies, that include patients in the acute setting, at follow up, and prior to 515 recurrence. One limitation of our study is that we have not analysed a cohort of individuals that 516 were sampled prior to VTE event. From a technological perspective, our study demonstrates the 517 need for orthogonal verification of any potential biomarker identified using antibody-based 518 proteomics screening [34, 35]. The same caution should be extended to findings generated using 519 other high throughput affinity proteomics technologies vulnerable to non-specific protein binding, 520 such as aptamer-based [74], where missense single nucleotide polymorphisms can affect binding 521 in a manner where a genetic difference drive associations, rather than protein levels (Figure S1 522 F) [75, 76]. Studies comparing different affinity proteomics technologies have found correlations 523 of proteins assayed with two or more platforms to range from highly concordant (r = 0.95) to 524 inversely correlated (r = -0.48) [75], highlighting further the need for orthogonal validation of any 525 potential biomarker identified.

526 The next steps towards the translation of our findings into a clinical setting is to develop and 527 establish standardised methods for quantification, to establish reference intervals and define cut 528 off values with respect to specificity and sensitivity. Furthermore, it remains to be established if 529 the incorporation of CFHR5 measurements into clinical decision rules or other scores can improve 530 predictive power. The inclusion of CFHR5 measurements as a diagnostic and/or risk predictive 531 marker in randomized clinical trials of acute VTE and VTE recurrence would be particularly 532 informative, as these are two areas of high clinical relevance in need of improved tools for clinical 533 decision making. Furthermore, while our study indicates that CFHR5 has a functional role in VTE 534 development, further studies are needed to understand the mechanism.

535 MATERIALS AND METHODS

536 **PATIENTS AND SAMPLES**

537 Discovery study

538 Venous thromboembolism biomarker study (VEBIOS)

539 VEBIOS is part of a collaboration between Karolinska University Hospital, Karolinska Institute and 540 Royal Institute of Technology (KTH) designed to identify new plasma biomarkers for VTE [27]. 541 VEBIOS comprises two different studies: (i) VEBIOS ER study is a prospective cohort study 542 carried out at the Emergency Room (ER) at the Karolinska University Hospital in Solna, Sweden, 543 between December 2010 and September 2013. All patients admitted with the suspicion of deep 544 vein thrombosis (DVT) in the lower limbs and/or pulmonary embolism (PE), over 18 years old 545 were eligible for the study. Exclusion criteria were patients with on-going anticoagulant treatment. 546 pregnancy, active cancer, short life expectancy or lack of capacity to leave approved consent. A 547 case was defined if a) VTE was confirmed by diagnostic imaging - compression venous 548 ultrasonography (CUS) in patients with suspected DVT in the lower limbs, and computed 549 tomography pulmonary angiography (CTPA) in patients with suspected PE, and b) anticoagulant 550 treatment was initiated based on the VTE diagnosis. Patients with no evidence of an acute VTE, 551 (neither by diagnostic imaging nor by Well's clinical criteria) that had a normal d-dimer test [5], 552 were referred as controls in the study. All participants were sampled before any anticoagulant 553 treatment. Whole blood was collected in citrate or EDTA anticoagulant at the ER and sent within 554 30 minutes to the Karolinska University Laboratory. After centrifugation at 2000g for 15 minutes, 555 plasma aliquots were snap frozen and stored at -80°C. Data collection: For each patient, doctors 556 filled in a questionnaire detailing (1) any provoking factors within one month preceding the visit to 557 the ER (2) current health situation, alcohol consumption and smoking habits; (3) family history of 558 VTE (4) ongoing antithrombotic (antiplatelet) treatment and (5) estrogen containing 559 contraceptives and hormone replacement therapy (women only). Information from the ER visit on 560 patient weight and height (when available) along with results from routine laboratory tests i.e.,

561 blood count, d-dimer, C-reactive protein (CRP), creatinine, international normalized ratio (INR) 562 and activated partial thromboplastin time (aPTT) were extracted from the medical records. In total, 563 158 patients were included (52 cases). For the present study, 48 cases were available for analysis 564 and 48 controls were matched as closely as possible by age and sex. Clinical characteristics of 565 the sample set is given in Table 1. (ii) VEBIOS Coagulation study is an on-going case-control 566 study established January 2011 of patients sampled at an outpatient coagulation clinic after 567 discontinuation of anticoagulant treatment after a verified first VTE (DVT to the lower limbs and/or 568 PE), matched with healthy controls from the population. Patients were between 18 to 70 years of 569 age, free from cancer, severe thrombophilia and pregnancy at inclusion [27]. In the present study, 570 we analysed an extended sample set of VEBIOS Coagulation comprising all available samples; 571 144 cases and 140 controls (Table S2, Tab 1). Approval for VEBIOS was granted by the regional 572 research ethics committee in Stockholm, Sweden (KI 2010/636-31/4) and all participants gave 573 informed written consent, in accordance with the Declaration of Helsinki.

574 **Replication cohorts**

575 The Swedish Karolinska Age Adjusted D-Dimer study (DFW-VTE study) includes patients with 576 clinically suspected acute VTE, prospectively recruited from the ER of Karolinska University 577 Hospital in Huddinge, Stockholm, as previously described [47]. The patients were out-patients 578 with low-to-high probability of acute PE or DVT in a lower limb. The study was approved by the 579 regional ethics review board in Stockholm (DNR 2013-2143-31-2), and all participants gave 580 informed written consent, in accordance with the Declaration of Helsinki. For the current study, 581 biobanked plasma aliquots were available for a subset of subjects comprising 15 patients with 582 PE, 39 with DVT, and 146 controls where VTE was excluded. Controls were identified based on 583 negative diagnostic imaging, or a low Well's score together with negative D-dimer. Clinical 584 characteristics are described in Table S2, Tab 2.

585 The *FARIVE study* is a French multicentre case-control study carried out between 2003-2009, as 586 previously described [77]. The study consists of patients with first confirmed VTE (DVT to the

lower limbs and/or PE) from 18 years of age, matched to hospital controls with no previous thrombotic event. All participants were free from cancer. The study was approved by the Paris Broussais-HEGP ethics committee in Paris (2002-034) and all participants gave informed written consent, in accordance with the Declaration of Helsinki. In the current study we used a subset of *FARIVE* samples (n=1158), as previously described [27] [78]. From most cases, blood was collected in the first week after diagnosis and during anticoagulant treatment initiation. Clinical characteristics are described in Table S2, Tab_3.

594 The Riesgo de Enfermedad TROmboembólica VEnosa (RETROVE) study is a prospective 595 case-control study of 400 consecutive patients with VTE (cancer associated thrombosis 596 excluded) and 400 healthy control volunteers. Individuals were recruited at the Hospital de la 597 Santa Creu i Sant Pau of Barcelona (Spain) between 2012 and 2016. Controls were selected 598 according to the age and sex distribution of the Spanish population (2001 census) [79]. All 599 individuals were \geq 18 years. All procedures were approved by the Institutional Review Board of 600 the Hospital de la Santa Creu i Sant Pau, and all participants gave informed written consent, in 601 accordance with the Declaration of Helsinki. In the current study, samples from 308 cases and 602 360 controls were used. Clinical characteristics are described in Table S2, Tab 4.

603 The Marseille Thrombosis Association study (MARTHA) is a population based single centre study, 604 as previously described [78]. Recruitment in MARTHA started in 1994 at Timone Hospital in 605 Marseille (France) and is still ongoing. The cohort from 1994 and 2008, includes a total of 1542 606 VTE-cases (66% women) that donated blood for further analysis. Ethical approval was granted 607 from the Department of Health and Science, France (2008-880 & 09.576) and all participants 608 gave informed written consent, in accordance with the Declaration of Helsinki. In the current study, 609 proteomics data generated for 1322 sampled MARTHA cases was used. For 669 of the MARTHA 610 cases, follow up data up to 12 years post-event was available and used to analyse risk of recurrent 611 VTE. For a subset of 774 cases data for thrombin generation potential (TGP) was available [80],

which was used to analyse the association between CFHR5 and blood coagulability. Clinicalcharacteristics are described in Table S2, Tab 5.

614 The COVID-19 biomarker and Immunity (COMMUNITY) study is a single centre study of 112 615 patients with COVID-19 admitted to a general ward, intermediate units, or intensive care units at Danderyd Hospital, Stockholm Sweden between April 15th and May 27th, 2020. Inclusion required 616 617 confirmed SARS-CoV2 infection, based on viral RNA detection by reverse-transcriptase 618 polymerase chain reaction of nasopharyngeal or oropharyngeal swabs, or clinical presentation of 619 COVID-19. Exclusion criteria were age <18 years. Patients were followed longitudinally from 620 inclusion, and blood samples were collected shortly after hospital admission and every 2-3 days 621 during the hospital stay. Procedures for blood sampling and plasma preparation have been 622 previously described [59]. Demographic data, routine lab results, comorbidity and information and 623 variables, reflecting clinical deterioration, including respiratory support were obtained from 624 medical records. Patients were divided into groups based on respiratory support required at the 625 time of sampling ('Respiratory support Index' or RI): RI = 0; no respiratory support, RI = 1; \leq 5L of 626 oxygen on nasal cannula or mask, RI = 2; >5L of oxygen on nasal cannula or mask, RI = 3; non-627 invasive respiratory support and RI = 4; intubation. Level of respiratory support and oxygen 628 supplementation were set at by the treating physician. For the current study, 339 samples 629 collected from 112 patients were analysed, with at least 2 samples for 71 patients (63.4%). The 630 study was approved by the National Ethical Board (EPM 2020-01653). Clinical characteristics are 631 described in Table S2, Tab 6.

632 ANALYSIS OF PLASMA BY TARGETED PROTEOMICS

Plasma proteomic profiles in *VEBIOS ER* were generated using multiplexed suspension bead arrays (SBA) with 758 antibodies selected from the Human Protein Atlas (HPA) project, targeting 408 proteins (Table S1), using identical design, procedures and methods as previously described [27]. Briefly, paired samples were randomly distributed within the same 96-well area. Two suspension bead arrays composed of 380 antibodies and 4 controls were used to sequentially

638 generate profiles of the 96 samples in parallel. Proteomics profiling was performed in both EDTA 639 and Citrate plasma. Median fluorescence intensity (MFI) values were obtained from the 640 suspension bead array assay by detecting at least 32 beads per ID and sample with the FlexMap 641 3D instrument (Luminex[®] Corp) and were normalized by (1) probabilistic quotient normalization 642 as accounting for any potential sample dilution effects [81], and (2) multidimensional MA (M=log 643 ratio: A=mean average, scales) normalization to minimize the difference amount the subgroups 644 of the samples generated by experimental factor as multiple batches [82]. Association of target 645 proteins with VTE was tested using linear regression analysis while adjusting for age and gender. 646 Log-transformation was applied to reduce any skewness in the proteomic data distribution. The 647 analyses were performed using the R statistical computing software [83].

648 Immunocapture mass spectrometry (IC-MS)

IC-MS was performed in triplicate, as previously described [27] using the HPA059937 antibody (Atlas Antibodies) or rabbit immunoglobulin G (rlgG) as a negative control. Digested samples were analyzed using an Ultimate 3000 RSLC nanosystem (Dionex) coupled to a Q-Exactive HF (Thermo). Uniprot complete human proteome (update 20180131) was used to query the raw data, with the engine Sequest and Proteome Discoverer platform (PD, v1.4.0.339, Thermo Scientific). An internal database containing the most common proteins detected by IC-MS in plasma was used to calculate Z-scores [36].

656 In-house developed bead based dual binder immunoassays

A Suspension Bead Array (SBA) was built with the capture antibodies raised against human extracellular sulfatase 1-SULF1 (rabbit polyclonal HPA059937) and human CFHR5 (rabbit polyclonal HPA072446 and HPA073894) covalently coupled to color-coded magnetic beads as previously described (Drobin et al., 2013; Neiman et al., 2013). Bead-coupled rabbit IgG (Bethyl Laboratories Inc.) and mouse-IgG and bare beads were included as negative controls. Mouse anti-human SULF1 antibodies Abnova ABIN525031, Abcam ab172404, Thermofisher PA5-113112, Human Protein Atlas antibodies HPA054728 and HPA051204, and mouse monoclonal

anti-human CFHR5 (R&D systems, MAB3845) antibody were labelled with biotin and used as 664 665 detection antibodies in combination with their respective capture antibodies.--Citrate plasma 666 samples were thawed on ice and centrifuged for 1 min at 2000 rpm and diluted in buffer polyvinyl 667 10% 10% rlqG (PVXcas rlgG; polyvinyl alcohol, Sigma Aldrich casein P8136; 668 polyvinylpyrrolidone, Sigma Aldrich PVP360; Blocker Casein, Thermo 37528), heated at 56°C for 669 30 min and incubated with the SBA overnight. The detection antibody was used at 1ug/mL for 90 670 min, and streptavidin- R-phycoerythrin (R-PE) conjugate (Life Technologies; SA10044) was used 671 for the fluorescence read out in Luminex platform. The dual binder assays based on HPA059937. 672 HPA072446 or HPA073894 as capture antibodies together with the monoclonal anti-human 673 CFHR5 were used to measure samples in the VEBIOS ER cohort, and correlations between MIF 674 values obtained with the 3 different dual binder assays and the original single binder assay with 675 HPA059937 were determined.

676 Absolute quantification of CFHR5, C3 and D-dimer

677 For CFHR5 quantification, rabbit polyclonal anti-human CFHR5 HPA072446 (Atlas Antibodies) 678 and mouse monoclonal anti-human CFHR5 (R&D systems; MAB3845) antibodies were used in a 679 dual binder assay. Human recombinant CFHR5 (R&D systems; 3845-F5) spiked into chicken 680 plasma (Sigma Aldrich, St. Louis, United States, P3266) was used as a standard. All samples 681 were diluted 1:300 in PVXcas 10% rlgG. For C3 guantification, mouse anti-human C3 and mouse 682 monoclonal anti-human C3 antibodies (Bsi0263, Bsi0190, respectively, Biosystems International) 683 were used in a dual binder assay. Human recombinant C3 (Sigma Aldrich, C2910) spiked into C3 684 depleted serum (Merck, 234403) was used as a standard. All samples were diluted 1:5000 and 685 analysed as described above. D-dimer was guantified by ELISA (D-Di 96 test, product #00947, 686 Asserachrom, France) following the manufacturer's instructions. In the DFW-VTE study, D-dimer 687 values were analysed at the Karolinska University Hospital Laboratory in fresh samples sent for 688 routine clinical chemistry analysis, as part of the work up in the ER.

689 Analysis of CFHR5 in COVID-19 patients in the *COMMUNITY* study

690 The HPA antibody HPA073894, targeting the CFHR5 protein, was included in a screening panel 691 using multiplexed suspension bead arrays (SBA) following a similar protein profiling protocol as 692 in the targeted plasma proteomics screening (see above). Association of CFHR5 plasma levels 693 with Respiratory support Index (RI) at baseline was tested using linear regression models. RI 694 groups were as follows: RI 0: no respiratory support required, RI 1: \leq 5 Litres of oxygen on nasal 695 cannula or mask. RI 2: > 5 Litres of oxygen on nasal cannula or mask. RI 3: non-invasive 696 ventilation/high-flow nasal cannula, or RI 4: intubation. To handle multiple time point 697 measurements, association of CFHR5 plasma levels with RI was further investigated using all 698 available longitudinal measurements using a linear mixed effect model as implemented in the 699 nlme R package. Analyses were adjusted for age, sex and body mass index.

700 **CFHR5 mRNA expression across human organs**

701 As part of the Human Protein Atlas (HPA, <u>www.proteinatlas.org/</u>), the average TPM value of all 702 individual samples for each human tissue in both the HPA and Genotype-Tissue Expression 703 Project (GTEx) transcriptomics datasets were used to estimate the respective gene expression 704 levels. To be able to combine the datasets into consensus transcript expression levels, a pipeline 705 was set up to normalize the data for all samples. In brief, all TPM values per sample were scaled 706 to a sum of 1 million TPM (denoted pTPM) to compensate for the non-coding transcripts that had 707 been previously removed. Next, all TPM values of all samples within each data source were 708 normalized separately using Trimmed mean of M values to allow for between-sample 709 comparisons. The resulting normalized transcript expression values (nTPM) were calculated for 710 each gene in each sample. For further details see www.proteinatlas.org/about/assays+annotation 711 - normalization rna. Analysis of liver single cell transcriptomes and visualisation was performed 712 as part of the HPA single-cell transcriptomics map [41] from data generated in [84].

713 **CFHR5 mRNA co-expression analysis**

Liver bulk RNAseq data analysed in this study was part of the Genotype-Tissue Expression
(GTEx) Project (gtexportal.org) [85] (dbGaP Accession phs000424.v7.p2) (n=226). Pearson

716 correlation coefficients were calculated between CFHR5 expression values and those for all other 717 mapped protein coding genes across the sample set. Weighted correlation network (WGCNA) 718 analysis: The R package WGCNA was used to perform co-expression network analysis for gene 719 clustering, on log2 expression values. The analysis was performed according to 720 recommendations in the WGCNA manual. Genes with too many missing values were excluded 721 using the goodSamplesGenes() function. The remaining genes were used to cluster the samples, 722 and obvious outlier samples were excluded. Using these genes and samples a soft-thresholding 723 power was selected and the networks were constructed using a minimum module size of 15 and 724 merging threshold of 0.05. Eigengenes were calculates from the resulting clusters and eigengene 725 dendrograms were constructed using the plotEigengeneNetworks() function.

726 Measurement of Thrombin Generation Potential

727 Thrombin generation potential (TGP) was measured in fresh frozen platelet poor plasma (PPP)

vising the Calibrated Automated Thrombogram (CAT®) method according to the manufacturer's

instructions. Analyses in MARTHA and RETROVE are as previously described [80, 86].

Output parameters recorded were lagtime (min), the time to the initial generation of thrombin after induction; Endogenous Thrombin Potential (ETP)(nmol/min), equal to the area under the Thrombogram curve; Peak (nmol/L), the maximum amount of thrombin produced after induction by 5pM tissue factor.

734 Effect of recombinant CFHR5 on platelet activation

Blood was drawn from healthy volunteers free from any anti-platelet therapy for at least 10 days and anticoagulated with sodium citrate. All donors signed informed consent, in accordance with approval of the Human Ethics Committee of the Medical University of Vienna (EK237/2004) and the Declaration of Helsinki. Whole blood was centrifuged (120 *g*, 20 minutes, room temperature) and platelet-rich plasma (PRP) harvested. To obtain isolated platelets, PRP was diluted with PBS and treated with PGI₂ (100 ng/ml), centrifuged for 90 sec at 3000 x g and platelets were resuspended in PBS. This step was repeated twice. Platelet-rich plasma (PRP) or isolated

742 platelets were incubated with recombinant CFHR5 in PBS (6 µg/ml, 3845-F5, R&D systems) or PBS alone for 10 minutes before treatment with varying concentrations of ADP (1-5 µM), TRAP-743 744 6 (3-15 µM) or convluxin (1-6 ng/ml) for 15 minutes. Platelets were subsequently incubated with 745 primary antibodies: anti-human CD62P-AF647 (AK4), anti-human CD63-PE (H5C6) or anti-746 human CD41/CD61-FITC (PAC-1) (all Biolegend) for 20 minutes, washed (PBS then 500 g for 747 10 minutes), then fixed with 1 % paraformaldehyde and incubated with Alexa Fluor 647-748 streptavidin (Jackson Immuno Research, Ely, UK) for 20 minutes. Samples were analysed by flow 749 cytometry (Cytoflex, Beckman Coulter GmbH, Krefeld, Germany) and data processed using 750 Cytexpert (Beckman Coulter GmbH, Krefeld, Germany).

751 Genome wide genotyping methods

752 RETROVE samples were typed with the Illumina Infinium Global Screening Array (GSA) v2.0 753 array at the Spanish National Cancer Research Centre in the Human Genotyping lab, a member 754 of CeGen. After genotyping, all monomorfic and unannotated variants were removed as well as 755 polymorphisms with call rate <95% and those whose genotype distributions deviate from Hardy-756 Weinberg equilibrium at p < 0.000001. Remaining polymorphisms were then imputed using the 757 TOPMed r2 reference panel using Eagle v2.4. FARIVE participants were genotyped using the 758 Illumina Infinium Global Screening Array v3.0 (GSAv3.0) microarray at the Centre National de 759 Recherche en Génomique Humaine (CNRGH). A control quality has been performed on 760 individuals and genetic variants using Plink v1.9 and the R software v3.6.2 (Chang et al., 2015). 761 Individuals with at least one of the following criteria were excluded: discordant sex information 762 (N=20), relatedness individuals (N=9) identified by pairwise clustering of identity by state 763 distances (IBS), genotyping call rate lower than 99% (N=5), heterozygosity rate higher/lower than 764 the average rate +/- 3 standard deviation (N=34). These criteria led to a final sample composed 765 of 1,266 individuals. Among the 730,059 genotyped variants, we excluded 145,238 variants with 766 incorrect annotation, 656 variants with deviation from Hardy-Weinberg equilibrium (HWE) in 767 controls using the statistical threshold of $p < 10^{-6}$, 47,286 variants with a Minor Allele Count (MAC)

lower than 20, 1,774 variants with a call rate lower than 95%. Finally, 535,105 markers passed the control quality and were used for the imputation. The Imputation was performed with Minimac4 using the 1000 Genomes phase 3 version 5 reference panel [87]. *MARTHA* samples were typed with Illumina Human 610-/ 660W- Quad Beadchip. Quality control procedures of produced genome-wide genotype data in *MARTHA* participants have already been extensively described [88-90]. After further exclusion of individuals with cancer and systemic lupus erythematosus, 1525 participants remained for association testing.

775 Genome Wide Association Study on CFHR5 plasma levels

All SNPs with imputation quality criterion greater than 0.30 and minor allele frequency greater than 0.01 in each participating cohorts were tested for association with CFHR5 plasma levels. Associations were assessed using a linear regression model adjusted for age, sex and studyspecific principal components derived from genome-wide genotype data. Results obtained in the different contributing cohorts were then meta-analyzed through a random effect model as implemented in the GWAMA software [91].

782 ACKNOWLEDGEMENTS

783 The study was supported by grants from Stockholm City Council (SLL) to JO (2017-0842/0587, 784 2020-0346), from Familien Erling Personssons Stiftelse to MU, Knut och Alice Wallenberg 785 foundation to JO (2020.0182, 2020.0241), from Swedish Heart Lung Foundation to LB (20170759, 786 20170537), National Research Council (VR) to LB (2019-01493), HelseNord to JO (HNF1544-787 20). The Human Protein Atlas (HPA) is funded by The Knut and Alice Wallenberg Foundation. 788 MARTHA and FARIVE related genetics research programs were funded by the 789 GENMED Laboratory of Excellence on Medical Genomics [ANR-10-LABX-0013], a research 790 program managed by the National Research Agency (ANR) as part of the French Investment for 791 the Future, and supported by the French INvestigation Network on Venous Thrombo-Embolism 792 (INNOVTE). MARTHA and FARIVE genetic data analyses benefit from the technical support of 793 the CBiB computing centre of the University of Bordeaux. GM and D-AT are supported by the 794 EPIDEMIOM-VT Senior Chair from the University of Bordeaux initiative of excellence IdEX. GM 795 benefited from the EUR DPH, a PhD program supported within the framework of the PIA3 796 (Investment for the future). Project reference 17-EURE-0019. The RETROVE study was 797 supported by grants PI12/00612 and PI15/0026. Genotyping of the RETROVE samples was 798 supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF.

799 Data usage: We used data from the Genotype-Tissue Expression (GTEx) Project (<u>gtexportal.org</u>)

800 [40]. The GTEx project was supported by the Office of the Director of the National Institutes of

801 Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.

802 **Figures**: Some parts of the figures were created with BioRender.com.

Johansson, M., L. Johansson, and M. Lind, Incidence of venous thromboembolism in

803 References

1.

804

805 northern Sweden (VEINS): a population-based study. Thromb J, 2014. 12(1): p. 6. 806 2. Heit, J.A., Epidemiology of venous thromboembolism. Nature reviews. Cardiology, 2015. 807 **12**(8): p. 464-74. 808 Sogaard, K.K., et al., 30-year mortality after venous thromboembolism: a population-3. 809 based cohort study. Circulation, 2014. 130(10): p. 829-36. 810 Martinez, C., et al., Epidemiology of first and recurrent venous thromboembolism: A 4. 811 population-based cohort study in patients without active cancer. Thrombosis and 812 Haemostasis, 2014. 112(2): p. 255-263. 813 5. Wells, P.S., et al., Evaluation of D-dimer in the diagnosis of suspected deep-vein 814 thrombosis. N Engl J Med, 2003. 349(13): p. 1227-35. 815 Wells, P.S., et al., Excluding pulmonary embolism at the bedside without diagnostic 6. 816 imaging: management of patients with suspected pulmonary embolism presenting to the 817 emergency department by using a simple clinical model and d-dimer. Ann Intern Med, 818 2001. **135**(2): p. 98-107. 819 7. Mittadodla, P.S., et al., CT pulmonary angiography: an over-utilized imaging modality in 820 hospitalized patients with suspected pulmonary embolism. J Community Hosp Intern 821 Med Perspect, 2013. 3(1). 822 8. Sikkens, J.J., et al., How Much Overtesting Is Needed to Safely Exclude a Diagnosis? A 823 Different Perspective on Triage Testing Using Bayes' Theorem. PLoS One, 2016. 11(3): 824 p. e0150891. 825 9. Pernod, G., et al., *D-Dimer Use and Pulmonary Embolism Diagnosis in Emergency* 826 Units: Why Is There Such a Difference in Pulmonary Embolism Prevalence between the 827 United States of America and Countries Outside USA? PLoS One, 2017. 12(1): p. 828 e0169268. 829 10. Francis, S., et al., Highly Elevated Quantitative D-Dimer Assay Values Increase the 830 Likelihood of Venous Thromboembolism. TH Open, 2019. 3(1): p. e2-e9. 831 Jacobs, B., A. Obi, and T. Wakefield, *Diagnostic biomarkers in venous thromboembolic* 11. 832 disease. J Vasc Surg Venous Lymphat Disord, 2016. 4(4): p. 508-17. 833 12. Eichinger, S., et al., Risk assessment of recurrence in patients with unprovoked deep vein 834 thrombosis or pulmonary embolism: the Vienna prediction model. Circulation, 2010. 835 **121**(14): p. 1630-6. 836 13. Tosetto, A., et al., Predicting disease recurrence in patients with previous unprovoked 837 venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost, 838 2012. **10**(6): p. 1019-25. 839 14. Verhovsek, M., et al., Systematic review: D-dimer to predict recurrent disease after 840 stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern 841 Med, 2008. **149**(7): p. 481-90, W94. 842 Rodger, M.A., et al., Identifying unprovoked thromboembolism patients at low risk for 15. recurrence who can discontinue anticoagulant therapy. Canadian Medical Association 843 844 Journal, 2008. 179(5): p. 417-26. 845 16. Baglin, T., et al., Unprovoked recurrent venous thrombosis: prediction by D-dimer and 846 clinical risk factors. J Thromb Haemost, 2008. 6(4): p. 577-82.

847 848 840	17.	Bruinstroop, E., et al., <i>Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis.</i> J Thromb Haemost, 2009. 7 (4): p. 611. 8
049 050	10	011-0. Device I at al. Detient level mate analysis, effect of magazinement timing threshold
030 051	10.	Doukens, J., et al., Futient-level mela-analysis. effect of measurement liming, intesnola,
031 952		and patient age on ability of D-atmer testing to assess recurrence risk after unprovoked
0 <i>32</i> 052	10	Venous inromocemoousm. Ann intern Med, 2010. 155 (8): p. 525-51.
855 854	19.	susceptibility loci for venous thromboembolism. Blood, 2019. 134 (19): p. 1645-1657.
855	20.	Klarin, D., et al., Genome-wide association analysis of venous thromboembolism
856		identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet,
857		2019. 51 (11): p. 1574-1579.
858	21.	Thibord, F.e.a., <u>https://doi.org/10.1101/2022.03.04.22271003</u> .
859 860	22.	Morange, P.E. and D.A. Tregouet, <i>Current knowledge on the genetics of incident venous</i>
000 961	7 2	Montinelli L. V. De Stefene, and D.M. Mennyeei. Inhevited wigh factors for veneral
862	23.	thromboembolism. Nat Rev Cardiol, 2014. 11 (3): p. 140-56.
863	24.	Goldhaber, S.Z., Risk factors for venous thromboembolism. J Am Coll Cardiol, 2010.
864		56 (1): p. 1-7.
865	25.	Crous-Bou, M., L.B. Harrington, and C. Kabrhel, Environmental and Genetic Risk
866		Factors Associated with Venous Thromboembolism. Semin Thromb Hemost, 2016. 42(8):
867		p. 808-820.
868	26.	Jensen, S.B., et al., Discovery of novel plasma biomarkers for future incident venous
869		thromboembolism by untargeted synchronous precursor selection mass spectrometry
870		proteomics. Journal of Thrombosis and Haemostasis, 2018. 16: p. 1763-1774.
871	27.	Bruzelius, M., et al., PDGFB, a new candidate plasma biomarker for venous
872		thromboembolism: results from the VEREMA affinity proteomics study. Blood, 2016.
873		128 (23): p. 59-67.
874	28.	Blostein, M.D., et al., Elevated plasma gas6 levels are associated with venous
875		thromboembolic disease. J Thromb Thrombolysis, 2011. 32 (3): p. 272-8.
876	29.	Song, Y., et al., Increased expressions of integrin subunit beta1, beta2 and beta3 in
877		patients with venous thromboembolism: new markers for venous thromboembolism. Int J
878		Clin Exp Med, 2014. 7(9): p. 2578-84.
879	30.	Memon, A.A., et al., Identification of novel diagnostic biomarkers for deep venous
880		thrombosis. British Journal of Haematology, 2018. 181: p. 378-385.
881	31.	Deutsch, E.W., et al., Advances and Utility of the Human Plasma Proteome. J Proteome
882		Res. 2021. 20 (12): p. 5241-5263.
883	32.	Butler, L.M., et al., Analysis of Body-wide Unfractionated Tissue Data to Identify a Core
884	-	Human Endothelial Transcriptome. Cell Syst. 2016. 3 (3): p. 287-301 e3.
885	33.	Mathews, J.A., et al., Considerations for Soluble Protein Biomarker Blood Sample
886		<i>Matrix Selection</i> . AAPS J. 2020. 22 (2): p. 38.
887	34.	Baker, M., <i>Reproducibility crisis: Blame it on the antibodies</i> , Nature, 2015, 521 (7552); p.
888	-	274-6.
889	35.	Weller, M.G., <i>Quality Issues of Research Antibodies</i> . Anal Chem Insights, 2016. 11: p.
890		21-7.
891	36.	Fredolini, C., et al., Systematic assessment of antibody selectivity in plasma based on a
892		resource of enrichment profiles. Sci Rep, 2019. 9(1): p. 8324.

893	37.	Schwenk, J.M., et al., The Human Plasma Proteome Draft of 2017: Building on the
894		Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays. J
895		Proteome Res, 2017. 16(12): p. 4299-4310.
896	38.	Desiere, F., et al., The PeptideAtlas project. Nucleic Acids Res, 2006. 34(Database
897		issue): p. D655-8.
898	39.	Uhlen, M., et al., Proteomics. Tissue-based map of the human proteome. Science, 2015.
899		347 (6220): p. 1260419.
900	40.	Consortium, G.T., The Genotype-Tissue Expression (GTEx) project. Nat Genet, 2013.
901		45 (6): p. 580-5.
902	41.	Karlsson, M., et al., A single-cell type transcriptomics map of human tissues. Sci Adv,
903		2021. 7(31).
904	42.	Ashburner, M., et al., Gene ontology: tool for the unification of biology. The Gene
905		Ontology Consortium. Nat Genet, 2000. 25(1): p. 25-9.
906	43.	Gene Ontology, C., The Gene Ontology resource: enriching a GOld mine. Nucleic Acids
907		Res, 2021. 49 (D1): p. D325-D334.
908	44.	Langfelder, P. and S. Horvath, WGCNA: an R package for weighted correlation network
909		analysis. BMC Bioinformatics, 2008. 9: p. 559.
910	45.	Szklarczyk, D., et al., STRING v11: protein-protein association networks with increased
911		coverage, supporting functional discovery in genome-wide experimental datasets.
912		Nucleic Acids Res. 2019. 47 (D1): p. D607-D613.
913	46.	Norgaard, I., S.F. Nielsen, and B.G. Nordestgaard, Complement C3 and High Risk of
914		Venous Thromboembolism: 80517 Individuals from the Copenhagen General Population
915		<i>Study</i> . Clin Chem, 2016. 62 (3): p. 525-34.
916	47.	Farm, M., et al., Age-adjusted D-dimer cut-off leads to more efficient diagnosis of venous
917		thromboembolism in the emergency department: a comparison of four assays. J Thromb
918		Haemost, 2018. 16 (5): p. 866-875.
919	48.	Zhu, T., et al., Association of influenza vaccination with reduced risk of venous
920		thromboembolism. Thromb Haemost, 2009. 102(6): p. 1259-64.
921	49.	Llobet, D., et al., <i>Platelet hyperaggregability and venous thrombosis risk: results from</i>
922		the RETROVE project. Blood Coagul Fibrinolysis, 2021. 32(2): p. 122-131.
923	50.	Oudot-Mellakh, T., et al., Genome wide association study for plasma levels of natural
924		anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. Br
925		J Haematol, 2012. 157 (2): p. 230-9.
926	51.	Sauter, R.J., et al., Functional Relevance of the Anaphylatoxin Receptor C3aR for
927		Platelet Function and Arterial Thrombus Formation Marks an Intersection Point
928		Between Innate Immunity and Thrombosis. Circulation, 2018. 138(16): p. 1720-1735.
929	52.	Afshar-Kharghan, V., Complement and clot, Blood, 2017. 129 (16): p. 2214-2215.
930	53.	Subramaniam, S., et al., Distinct contributions of complement factors to platelet
931		activation and fibrin formation in venous thrombus development. Blood, 2017, 129 (16):
932		p. 2291-2302.
933	54.	McRae, J.L., et al., Human factor H-related protein 5 has cofactor activity, inhibits C3
934		convertase activity, binds heparin and C-reactive protein, and associates with
935		<i>lipoprotein.</i> J Immunol. 2005. 174 (10): p. 6250-6.
936	55.	Wang, H., et al., <i>D</i> -dimer, thrombin generation, and risk of a first venous thrombosis in
937		the elderly. Res Pract Thromb Haemost, 2021. 5(5): p. e12536.

938	56.	Magro, C., et al., Complement associated microvascular injury and thrombosis in the
939		pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res, 2020.
940		220: p. 1-13.
941	57.	Wu, Z. and J.M. McGoogan, <i>Characteristics of and Important Lessons From the</i>
942		Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
943		72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA,
944		2020. 323 (13): p. 1239-1242.
945	58.	Poissy, J., et al., Pulmonary Embolism in Patients With COVID-19: Awareness of an
946		Increased Prevalence. Circulation, 2020. 142(2): p. 184-186.
947	59.	von Meijenfeldt, F.A., et al., Prothrombotic changes in patients with COVID-19 are
948		associated with disease severity and mortality. Res Pract Thromb Haemost, 2021. 5(1): p.
949		132-141.
950	60.	Audu, C.O., et al., Inflammatory biomarkers in deep venous thrombosis organization,
951		resolution, and post-thrombotic syndrome. J Vasc Surg Venous Lymphat Disord, 2020.
952		8 (2): p. 299-305.
953	61.	Mosevoll, K.A., et al., Altered plasma levels of cytokines, soluble adhesion molecules
954		and matrix metalloproteases in venous thrombosis. Thromb Res, 2015. 136(1): p. 30-9.
955	62.	van Hylckama Vlieg, A., et al., The risk of a first and a recurrent venous thrombosis
956		associated with an elevated D-dimer level and an elevated thrombin potential: results of
957		<i>the THE-VTE study</i> . J Thromb Haemost, 2015. 13 (9): p. 1642-52.
958	63.	McRae, J.L., et al., Human factor H-related protein 5 (FHR-5). A new complement-
959		associated protein. J Biol Chem, 2001. 276(9): p. 6747-54.
960	64.	Cserhalmi, M., et al., Regulation of regulators: Role of the complement factor H-related
961		proteins. Semin Immunol, 2019. 45: p. 101341.
962	65.	Zipfel, P.F., et al., Factor H and disease: a complement regulator affects vital body
963		<i>functions</i> . Mol Immunol, 1999. 36 (4-5): p. 241-8.
964	66.	Murphy, B., et al., Factor H-related protein-5: a novel component of human glomerular
965		<i>immune deposits</i> . Am J Kidney Dis, 2002. 39 (1): p. 24-7.
966	67.	Csincsi, A.I., et al., Factor H-related protein 5 interacts with pentraxin 3 and the
967		extracellular matrix and modulates complement activation. J Immunol, 2015. 194 (10): p.
968		4963-73.
969	68.	Markiewski, M.M., et al., Complement and coagulation: strangers or partners in crime?
970		Trends Immunol, 2007. 28 (4): p. 184-92.
971	69.	Wu, Z., et al., Time Course of a Second Outbreak of COVID-19 in Beijing, China, June-
972		July 2020. JAMA, 2020. 324 (14): p. 1458-1459.
973	70.	Marini, J.J. and L. Gattinoni, Management of COVID-19 Respiratory Distress. JAMA,
974		2020. 323 (22): p. 2329-2330.
975	71.	Varga, Z., et al., Endothelial cell infection and endotheliitis in COVID-19. Lancet, 2020.
976		395 (10234): p. 1417-1418.
977	72.	Ma, L., et al., Increased complement activation is a distinctive feature of severe SARS-
978		CoV-2 infection. bioRxiv, 2021.
979	73.	Klok, F.A., et al., Incidence of thrombotic complications in critically ill ICU patients with
980	-	<i>COVID-19.</i> Thromb Res, 2020. 191 : p. 145-147.
981	74.	Joshi, A. and M. Mayr, In Aptamers They Trust: The Caveats of the SOMAscan
982		Biomarker Discovery Platform from SomaLogic. Circulation. 2018. 138(22): p. 2482-
983		2485.

984	75.	Pietzner, M., et al., Synergistic insights into human health from aptamer- and antibody-
985		based proteomic profiling. Nat Commun, 2021. 12(1): p. 6822.
986	76.	Olson, N.C., et al., Soluble Urokinase Plasminogen Activator Receptor: Genetic
987		Variation and Cardiovascular Disease Risk in Black Adults. Circ Genom Precis Med,
988		2021. 14 (6): p. e003421.
989	77.	Zhu, T., et al., Association of influenza vaccination with reduced risk of venous
990		thromboembolism. Thrombosis and Haemostasis, 2009. 102(12): p. 1259-1264.
991	78.	Trégouët, D.A., et al., Common susceptibility alleles are unlikely to contribute as
992		strongly as the FV and ABO loci to VTE risk: Results from aGWAS approach. Blood,
993		2009. 113 (21): p. 5298-5303.
994	79.	Vazquez-Santiago, M., et al., Platelet count and plateletcrit are associated with an
995		increased risk of venous thrombosis in females. Results from the RETROVE study.
996		Thromb Res, 2017. 157 : p. 162-164.
997	80.	Rocanin-Arjo, A., et al., A meta-analysis of genome-wide association studies identifies
998		<i>ORM1 as a novel gene controlling thrombin generation potential.</i> Blood, 2014. 123 (5): p.
999		777-785.
1000	81.	Dieterle, F., et al., Probabilistic quotient normalization as robust method to account for
1001		dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal
1002		Chem, 2006. 78 (13): p. 4281-90.
1003	82.	Hong, M.G., et al., Multidimensional Normalization to Minimize Plate Effects of
1004		Suspension Bead Array Data. J Proteome Res, 2016. 15(10): p. 3473-3480.
1005	83.	Ihaka, R.G., R, R: A Language for Data Analysis and Graphics. Journal of
1006		Computational and Graphical Statistics, 1996. 5(3): p. 299-314.
1007	84.	MacParland, S.A., et al., Single cell RNA sequencing of human liver reveals distinct
1008		intrahepatic macrophage populations. Nat Commun, 2018. 9(1): p. 4383.
1009	85.	Consortium, G.T., Human genomics. The Genotype-Tissue Expression (GTEx) pilot
1010		analysis: multitissue gene regulation in humans. Science, 2015. 348(6235): p. 648-60.
1011	86.	Martin-Fernandez, L., et al., Genetic Determinants of Thrombin Generation and Their
1012		Relation to Venous Thrombosis: Results from the GAIT-2 Project. PLoS One, 2016.
1013		11 (1): p. e0146922.
1014	87.	Das, S., et al., Next-generation genotype imputation service and methods. Nat Genet,
1015		2016. 48 (10): p. 1284-1287.
1016	88.	Germain, M., et al., Genetics of venous thrombosis: insights from a new genome wide
1017		association study. PLoS One, 2011. 6(9): p. e25581.
1018	89.	Antoni, G., et al., Combined analysis of three genome-wide association studies on vWF
1019		and FVIII plasma levels. BMC Med Genet, 2011. 12: p. 102.
1020	90.	Germain, M., et al., Meta-analysis of 65,734 individuals identifies TSPAN15 and
1021		SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet,
1022		2015. 96 (4): p. 532-42.
1023	91.	Magi, R. and A.P. Morris, GWAMA: software for genome-wide association meta-
1024		analysis. BMC Bioinformatics, 2010. 11: p. 288.
1025		-

Figure 1



medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint Figure: WaPlasmaeproteomics) profiling: dentifies & Guerra as associated with by the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(A) Overview of the VEBIOS ER discovery cohort. 758 HPA antibodies, targeting 408 candidate proteins, were used to analyse plasma samples using affinity proteomics. Log fold changes in antibody MFI (mean fluorescent intensity) signal were calculated between VTE cases and controls in (B) citrate or (C) EDTA anticoagulated plasma; coloured circles indicate antibodies that generated signals significantly associated with VTE in both. MFI signals generated by these antibodies for controls and cases in (D) citrate plasma and (E) EDTA plasma. (F) Immunocapture-mass spectrometry identification of protein targets of HPA059937. (G) Dual binder assays were developed using an anti-CFHR5 detection antibody, combined with (i) HPA059937 (raised against SULF1) (ii), anti-CFHR5 HPA073894 or (iii) anti-CFHR5 HPA072446 as capture antibodies. CFHR5 levels in the citrated plasma samples were re-analysed, using the respective dual binder assays, to determine (vii-ix) levels (MFI) in controls vs. cases and (vii-ix) the correlation between the signal and those generated by the original single binder assay using HPA059937. Dual binder assay using capture antibody HPA072446 with a recombinant protein standard was used for absolute quantification of CFHR5 in samples from: (H) VEBIOS ER and (J) VEBIOS Coagulation. CFHR5 concentration was (i) measured in controls and cases, with associated OR (odds ratio per 1 standard deviation increase) or (ii) used to determine the correlation with C-reactive protein (CRP), or (iii) d-dimer concentration. ***p<0.0001, ***p<0.001, **p<0.01.

Figure 2

medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 2: CFHR5 is expressed in hepatocytes and is VTE-associated independent of C3

(A) mRNA expression of *CFHR5* across 55 different human tissue types. (B) Expression of *CFHR5* in different liver cell types, analysed by ssRNAseq. (C) STRING protein-protein interaction analysis for genes identified as potentially co-expressed with *CFHR5* in liver by correlation-based analysis of bulk mRNAseq. Coloured circles indicate closest network clusters. Complement component 3 (C3) concentration was measured in plasma from (D) *VEBIOS ER* or (E) *VEBIOS coagulation* to determine: (i) differences between controls and cases, or (ii) correlation with CFHR5 in controls (left) or cases (right). **p<0.01.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint C4@HA: was mpderments/factors/4e/bitsdiaguproteiner, which has mplements/factors/actions/ac

Figure 3

medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint (which was not eprified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No has allowed without permission.



Figure 3: CFHR5 concentration is associated with VTE in 5 independent studies. Plasma samples were generated as part of: (**A**) the Swedish *VEBIOS ER* or (**B**) the Swedish *DFW-VTE* study, both of which recruited patients presenting with suspected VTE. Samples were drawn pre-treatment, and cases and controls were identified based on confirmed or ruled out diagnosis. (**C**) The French *FARIVE* study recruited patients with confirmed acute VTE, with controls recruited from hospital patients treated for non-VTE causes. Samples were drawn within one week from diagnosis, during initiation of treatment. (**D**) The Swedish *VEBIOS Coagulation* or (**E**), Spanish *RETROVE* study recruited cases from patients who had a prior first time VTE, sampled post-treatment (6-12 months anticoagulants), with healthy controls recruited from the general population. CFHR5 concentration was measured in the respective samples using a dual binder assay **p<0.01, ***p<0.001, ****p<0.001 OR (1SD) = Odds ratio for 1 standard deviation elevation. CI= confidence interval.



Figure 4: GWAS analysis identifies a CFHR5 pQTL on Chromosome 1 q31.3 A meta-analysis of GWAS data for 7,135,343 SNPs tested for association with CFHR5 concentrations in a total sample of 2967 individuals from the *FARIVE*, *MARTHA* and RETROVE studies: (**A**) identified one genome-wide significant (p < 5E - 08) signal on chr1q31.3. (**B**) The lead SNP at this locus, rs10737681, maps between the *CFHR1* and *CFHR4* gene loci in the gene cluster of *CFHR1-5*. A borderline significant association (p = 9.83E - 08) with CFHR5 levels was observed at the rs10494747, mapping to the *ZBTB41* gene. Indicated in green is the rs143410348 recently identified with genome wide significance as associated with VTE risk [68].

Figure 5



Figure 5: Recombinant CFHR5 enhances platelet activation in platelet rich plasma. Platelet activation was measured by surface expression of (**A**) P-selectin, (**B**) activated GP IIb/IIIa or (**C**) CD63, following treatment of platelet rich plasma with different concentrations of (**i**) adenosine diphosphate (ADP) (**ii**) convulxin or (**iii**) TRAP6, following pre-incubation (10 minutes) with recombinant CFHR5, or PBS control. Each experiment is represented by an individual point and paired experiments connected by a dotted line. *p<0.05 **p<0.01 ***p<0.001 (p for trend bottom right).

Figure 6



Figure 6. Plasma CFHR5 concentration is associated with COVID-19 severity

(A) Schematic representation of the *COMMUNITY* cohort; (i) patients hospitalised with acute COVID-19 were included prospectively and followed longitudinally for disease severity (ii). Plasma was sampled at inclusion and, on average, every second day during hospital stay. (iii) In total, 359

medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint samples wwwerecool declared from will a qualifier fits darangings from a half scamples to esplay the preprint (R) in presente All rights reserved. No reuse allowed without permission. severity registered at time of sampling was classified into a Respiratory support Index (RI): RI=0: no Oxygen (O₂), RI=1: \leq 5 litres (L) of O₂ administered via cannula, RI=2: \geq 5 L O₂ via cannula or face mask, RI=3: Oxygenated air via Non-Invasive Ventilation (NIV) or High Flow Nasal Cannula (HFNC), RI=4: Intubated on ventilator. (C). CFHR5 plasma concentrations were measured in (i) all 339 samples to analyse the relationship with respiratory support index (RI) recorded at the time of sampling or (ii) in the 112 baseline samples to analyse the relationship with the maximum RI for that patient recorded at any subsequent time point (ii). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Table 1. (Clinical cha	aracteristics	of the	VEBIOS	ER sample set.
------------	--------------	---------------	--------	--------	----------------

	Cases (n=48)		Contro	ls (n=48)
Variables	n	Frequency	n	Frequency
Thrombosis localisation				
DVT, lower limbs	20	0.42	-	-
- Proximal	17	0.85	-	-
PE	21	0.44	-	-
DVT and PE	7	0.15	-	-
Sex and biometry				
Sex; women	22	0.45	22	0.45
Age (years) (mean ± SD and range)	56.6 ± 18.8	(19-89)	56.6 ± 16.8	(23-88)
Current smoking ‡	4	0.08	9	0.19
Family history				
VTE, First degree relative < 60 years old	14	0.29	6	0.12
Provoked risk factors (all)†	25	0.52	21	0.44
Estrogen containing contraceptives and hormone replacement therapy*	5	0.10	5	0.10
Concentration of markers measured	Median	IQR	Median	IQR
CFHR5 (ng/mL)	3361	(2997-3761)	2680	(2482-3075)
C3 (µg/mL)	653	(524-805)	656	(516-795)
D-dimer (ng/mL)	3604	(1335-7068)	521	(305-1128)
CRP (mg/L)	18	(8.5-42)	4.5	(2-21)
LPK (x10 ⁹ /L)	9.1	(7.2-10.2)	8	(7-10)
Hb (g/L)	135	(128-144)	138	(131-145)
TPK (x10 ⁹ /L)	206	(171-265)	240	(207-298)

DVT, deep vein thrombosis; **PE**, pulmonary embolism; **n**, numbers; **SD**, standard deviation; †, within one month from diagnosis or index date (immobilization with trauma, surgery, cast and/or orthosis and bedrest more than 3 days of sickness); ‡, within the last year; *, on-going treatment; **IQR**, interquartile range; **CFHR5**, Complement Factor H-related protein 5; **C3**, Complement 3; **CRP**, C-reactive protein; **LPK**, leucocytes; **Hb**, haemoglobin; **TPK**, thrombocytes. Missing values across all variables are <10%.

medRxiv preprint doi: https://doi.org/10.1101/2022.04.20.22274046; this version posted April 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **Table 2.** Risk of VTE associated with CFHRS concentration in five independent studies.

		VEBIOS ER	DFW-VTE	FARIVE	VEBIOS Coagulation	RETROVE
VTE ALL	OR (1SD)	2.54	1.80	1.24	1.55	1.29
	(95%CI)	(1.52-4.66)	(1.29-2.58)	(1.10-1.40)	(1.2-2.01)	(1.09-1.53)
	P-value	1.05E-03	7.65E-04	3.98E-04	8.85E-04	2.4E-03
	Cases	48	54	582	142	308
	Controls	48	146	576	135	360
CFHR5 rar	nge (ng/mL)	1216-6073	232-1170	450-4904	1378-4570	364-2341
Tertile 1	OR (1SD) (95%Cl)	Ref.	Ref.	Ref.	Ref.	Ref.
	P-value	NA	NA	NA	NA	NA
	Cases	10	9	165	39	91
	Controls	22	57	221	54	132
CFHR5 range (ng/mL)		1216-2653	232-476	450-1315	1378-2333	364-858
Tortilo 2	OR (1SD)	1.64	2.72	1.40	1.41	1.03
Tertile 2	(95%CI)	(0.58-4.80)	(1.15-6.86)	(1.05-1.86)	(0.78-2.55)	(0.69-1.52)
	P-value	0.36	0.03	0.02	0.25	0.88
	Cases	13	21	198	45	94
	Controls	19	46	188	47	128
CFHR5 rar	nge (ng/mL)	2675-3338	478-601	1317-1716	2335-2779	859-1063
Tortilo 2	OR (1SD)	9.05	2.93	1.75	2.51	1.67
Tertile 5	(95%CI)	(2.93-31.61)	(1.24-7.37)	(1.31-2.33)	(1.39-4.63)	(1.13-2.47)
	P-value	2.51E-04	0.02	1.28E-04	2.68E-03	9.90E-03
	Cases	25	24	219	58	123
	Controls	7	43	167	34	100
CFHR5 range (ng/mL)		3345-6073	603-1170	1717-4904	2782-4569	1064-2341